CDMO: Afraid of tech transfer? There’s no need!

by Heike Monange | May 6, 2021

Tech transfer appears on the agenda of almost every biotech company. After identifying a suitable molecule, biotechs need support from external partners on the way to commercialization. However, many fear that tech transfer could slow them down or that they may be locked in with royalty fees. Working with the right partner can make all the difference.

Tech transfers come in many flavors. They may be performed at an early stage, when a biotech is ready to enter pre-clinical phase for a novel therapeutic candidate. Or, they may happen at a later stage when production and analysis procedures have already been established and clinical data are available. We interviewed experts from the

Merck KGaA, Darmstadt, Germany

MilliporeSigma

BioReliance^® End-to-End Solutions team to demystify tech transfer and to share some best practices.

“Many biotechs do not have a long-term strategy, and that’s fine with us. After IND filing, some prefer to continue the development with a contract manufacturing and development organization (CDMO), others choose to either outlicense or sell their molecule to a pharma company,” Karima Medini, Senior Analytical Expert BioReliance^® End-to-End Solutions at

Merck KGaA, Darmstadt, Germany

MilliporeSigma

“Our clients can take their project from milestone to milestone and remain flexible in their decisions. We do not lock them in with royalty fees but support them to quickly and flawlessly transfer their processes to the receiving pharma company, or take it to market on their own once they are ready.”

Tech transfer to CDMO

In a typical early-stage project, a biotech company has identified a therapeutic molecule and seeks support from an external partner to set up the production processes and analytical methods needed to achieve investigational new drug (IND) filing.

For many startup companies, this is the first time they are ever involved in a tech transfer, so working with a CDMO partner that offers long-standing expertise can make all the difference.

“Over the years, we have established an optimized process that helps us understand where biotechs are on their journey and find out how we can best support them,” said Laetitia Botrel, Head of Business Planning and Operation, BioReliance^® End-to-End Solutions,

Merck KGaA, Darmstadt, Germany

MilliporeSigma

“Once we have identified the gaps and evaluated the risks associated with a project, we can advise our clients on how to move forward.”

What are the key success factors for a robust program that facilitates and accelerates tech transfer at any stage? Learn more about the combination of:

Multidisciplinary expert teams
Standardized information transfer
Single-use technologies
Analytical panels

Read the full article published on Labiotech.eu and reach out to us!

https://www.labiotech.eu/partner/demystifying-tech-transfer-cdmo/

Heike Monange

The team that delivers

Merck KGaA, Darmstadt, Germany's

MilliporeSigma's

BioReliance® End-to-End Solutions has the expertise and flexibility to support accelerated development and commercialization of biologics. With experience developing more than 250 biologics, the team can tailor analytical packages with validated quality attributes and flexibility to support companies in the development of molecules at all stages.

The analytical development and optimization team works closely with our process development and manufacturing teams to reduce uncertainty and mitigate risk at the very early stage of development so that to ensure the success. The strength of our analytical team lies in an open mindset and expertise to tailor programs fitting needs of the company and the pipeline asset.